Kenneth Beaty, MD
Family Medicine · Celina, TNNPI 1255364782
Payments from drug & device makers
Across 201 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$949
- Merck$329
- Axsome Therapeutics, Inc.$294
- Novo Nordisk$257
- Amgen$200
- AbbVie$185
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,86199%
- Other$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $949 |
| Merck | 28 | $329 |
| Axsome Therapeutics, Inc. | 15 | $294 |
| Novo Nordisk | 15 | $257 |
| Amgen | 13 | $200 |
| AbbVie | 10 | $185 |
| Pfizer | 12 | $181 |
| Corcept Therapeutics | 4 | $171 |
| Abbott | 5 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $123 |
| Lilly USA, LLC | 6 | $122 |
| Avanir Pharmaceuticals, Inc. | 5 | $99 |
| Otsuka America Pharmaceutical, Inc. | 6 | $98 |
| Phathom Pharmaceuticals, Inc. | 3 | $83 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $82 |
| Boehringer Ingelheim | 5 | $82 |
| Biohaven Pharmaceuticals, Inc. | 3 | $82 |
| Vanda Pharmaceuticals Inc. | 4 | $73 |
| Lundbeck LLC | 3 | $57 |
| Bayer | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $45 |
| Vertex | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
| Novartis | 2 | $31 |
| Acadia Pharmaceuticals Inc | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $28 |
| Johnson & Johnson | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,911 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $384,228 |
| EliquisApixaban | 339 | $195,974 |
| OzempicSemaglutide | 115 | $140,667 |
| JardianceEmpagliflozin | 131 | $128,960 |
| TrulicityDulaglutide | 69 | $76,614 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $67,621 |
| MounjaroTirzepatide | 59 | $65,689 |
| FarxigaDapagliflozin Propanediol | 82 | $60,396 |
| OtezlaApremilast | 11 | $57,266 |
| XareltoRivaroxaban | 64 | $54,541 |
| RexultiBrexpiprazole | 31 | $52,910 |
| LinzessLinaclotide | 69 | $44,204 |
| TrintellixVortioxetine Hydrobromide | 51 | $35,232 |
| EntrestoSacubitril/Valsartan | 32 | $34,746 |
| OxycontinOxycodone Hcl | 26 | $27,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Xarelto, Invokana | $17 | $459,13389 claims |
| PfizerEliquis, Nurtec Odt | $181 | $206,309350 claims |
| Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Spiriva Respimat, Glyxambi | $82 | $195,081227 claims |
| Novo NordiskOzempic, Rybelsus | $257 | $167,503131 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $122 | $142,302128 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Nexium | $949 | $85,453116 claims |
| AbbVieLinzess, Vraylar | $185 | $64,37083 claims |
| AmgenOtezla | $200 | $57,26611 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $98 | $52,91031 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $123 | $35,23251 claims |
| MerckJanuvia, Janumet | $329 | $35,12348 claims |
| NovartisEntresto | $31 | $34,74632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Celina
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.